Drs Samuel Klempner and Geoffrey Ku deep dive into all things esophageal squamous cell cancer, including detection, staging, and treatment.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999884. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer https://pubmed.ncbi.nlm.nih.gov/22646630/

Chemoradiotherapy of Locally Advanced Esophageal Cancer: Long-Term Follow-up of a Prospective Randomized Trial (RTOG 85-01). Radiation Therapy Oncology Group https://pubmed.ncbi.nlm.nih.gov/10235156/

Definitive Chemoradiotherapy With FOLFOX Versus Fluorouracil and Cisplatin in Patients With Oesophageal Cancer (PRODIGE5/ACCORD17): Final Results of a Randomised, Phase 2/3 Trial https://pubmed.ncbi.nlm.nih.gov/24556041/

Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study) https://pubmed.ncbi.nlm.nih.gov/34101496/

18-Fluorodeoxy-Glucose Positron Emission Computed Tomography as Predictive of Response After Chemoradiation in Oesophageal Cancer Patients https://pubmed.ncbi.nlm.nih.gov/26321501/

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer https://pubmed.ncbi.nlm.nih.gov/33789008/

Predictive Value of PD-L1 Expression in Response to Immune Checkpoint Inhibitors for Esophageal Cancer Treatment: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/36591463/

Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials https://pubmed.ncbi.nlm.nih.gov/36006624/

A Randomized Controlled Phase III Trial Comparing Two Chemotherapy Regimen and Chemoradiotherapy Regimen as Neoadjuvant Treatment for Locally Advanced Esophageal Cancer, JCOG1109 NExT Study https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.238

Delayed Surgical Intervention After Chemoradiotherapy in Esophageal Cancer: (DICE) Study https://pubmed.ncbi.nlm.nih.gov/37477039/

Initial Safety Assessment of the Endoscopically Injected Oncolytic Virus OBP-301 in Medically Inoperable Esophageal Cancer: NRG-GI007 https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.341

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Durvalumab With and After Chemoradiotherapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma: KUNLUN https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.TPS373

KEYNOTE-975 Study Design: A Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients With Esophageal Carcinoma https://pubmed.ncbi.nlm.nih.gov/33533655/

KEYNOTE-590: Phase III Study of First-Line Chemotherapy With or Without Pembrolizumab for Advanced Esophageal Cancer https://pubmed.ncbi.nlm.nih.gov/30735435/

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/35108470/